MAXCYTE INC (MXCT) Stock News
NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD
MXCT Latest News, Press Relases and Analysis
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CUE
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its...
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MarketBeat Week in Review – 01/20 - 01/24
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
MaxCyte Announces Retirement of Board Member Art Mandell
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte Announces Retirement of Board Member Art Mandell
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling...
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects...
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
MaxCyte to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte to Participate in Two Upcoming Investor Conferences
MaxCyte Appoints Cynthia Collins to its Board of Directors
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte Appoints Cynthia Collins to its Board of Directors
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology